AbbVie Defends Humira With Aggressive Discount In First EU Tender

AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.

Brown bear
AbbVie has laid down its defense of Humira's European market • Source: Shutterstock

AbbVie Inc. is ready for a fight to keep rivals away from having their piece of the biosimilar adalimumab market if reports of a price cut of 80% are anything to go by.

The discount in an, as yet, unknown market, is not expected to hurt AbbVie much financially. Even with the 80% discount, the gross margin on manufacturing Humira would be above...

More from Strategy

More from Business